Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]

NCT03428607 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

SCLC

Interventions

DRUG: AZD6738
DRUG: Olaparib

Sponsor

Samsung Medical Center